First safety check for new drug in kidney patients
NCT ID NCT07032272
Summary
This small, early-stage study aimed to understand how a new drug for autoimmune diseases is processed by the body in people with severe kidney problems. Researchers compared 8 participants with severe kidney impairment to 8 healthy volunteers to see if the drug behaves differently. The goal was to gather data to help doctors determine safe and effective doses for future patients with kidney issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami LLC
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research
Tampa, Florida, 33614, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States
Conditions
Explore the condition pages connected to this study.